| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Arch Venture Fund XIII LP | 10% Owner | 2026-03-06 | 488,090 | $25.61 | $12.50MBuy |
| Arch Venture Partners IX LLC | 10% Owner | 2026-03-06 | 488,090 | $25.61 | $12.50MBuy |
| Lynn Seely | President and CEO | 2026-02-11 | 7,455 | $23.39 | $174.37kSell |
| Stephen J. Hill | Chief Operating Officer | 2026-02-11 | 1,236 | $23.39 | $28.91kSell |
| Gary K. Lee | Chief Scientific Officer | 2026-02-11 | 1,671 | $23.39 | $39.08kSell |
| Stephen J. Hill | Chief Operating Officer | 2026-02-10 | 109 | $23.12 | $2.52kSell |
| Veronica Sanchez Bulis | VP Corporate Controller | 2026-02-10 | 254 | $23.12 | $5.87kSell |
| Gary K. Lee | Chief Scientific Officer | 2026-02-10 | 147 | $23.12 | $3.40kSell |
| Lynn Seely | President and CEO | 2026-02-10 | 438 | $23.12 | $10.13kSell |
| Veronica Sanchez Bulis | VP Corporate Controller | 2025-12-30 | 936 | $32.32 | $30.25kSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Robert Nelsen | 257.42% | 54,619,074 | $1.39B | Insider |
| Arch Venture Partners IX LLC | 184.48% | 39,143,667 | $998.16M | Insider |
| Glaxosmithkline PLC | 142.58% | 30,253,189 | $771.46M | Insider |
| Richard Klausner | 43.65% | 9,262,406 | $236.19M | Insider |
| Hans Edgar Bishop | 22.08% | 4,685,614 | $119.48M | Insider |
| Arch Venture Fund XIII LP | 8.71% | 1,848,755 | $47.14M | Insider |
| Decheng Capital LLC | 3.26% | 692,050 | $17.65M | Institution |
| Cathy Friedman | 2.70% | 572,740 | $14.60M | Insider |
| Sumant Ramachandra | 0.94% | 200,000 | $5.10M | Insider |
| Matthew Lang | 0.77% | 162,500 | $4.14M | Insider |